Sign in
Taking peopleNo phase

Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure

Key facts

Who runs it
Australian and New Zealand Intensive Care Research Centre
Where
Australia and Germany7 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
140 people, planned
Started
28 Nov 2022
Expected to end
31 Jan 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Venovenous ECMO
Record updated
9 August 2024

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Patients ≥18 to 65 years old
  • Acute hypoxemic respiratory failure characterised by new or worsening respiratory symptoms developing within 2 weeks prior to the onset of need for oxygen or respiratory support
  • Mechanical ventilation of <7 days
  • Moderate to severe respiratory failure, as demonstrated by two P:F ratios <150mmHg at least 6 hours apart. Arterial Blood Gases (ABG) with P:F ratio > 150mmHg are permitted between the two trial inclusion ABGs
  • Trial of proning (unless contraindicated)

Who cannot take part

  • Currently receiving any form of ECMO (e.g., venovenous, venoarterial, or hybrid configuration)
  • Previous hypersensitivity/anaphylactic reaction to heparin or heparin-induced thrombocytopenia
  • Cardiogenic cause of respiratory failure
  • Chronic hypercapnic respiratory failure defined as PaCO2 > 60 mmHg in the outpatient setting
  • Confirmed diffuse alveolar haemorrhage from vasculitis
  • Neurologic conditions, i.e. undergoing treatment for intracranial hypertension
  • Contraindications to anticoagulation (e.g., active GI bleeding, bleeding predisposition, severe trauma)
  • The patient will be extubated today or tomorrow (i.e. will not remain intubated and ventilated the day after tomorrow)
  • Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP/BIPAP used solely for sleep disordered breathing
  • Patient needing immediate VV ECMO (as per EOLIA criteria)
  • The patient is moribund and deemed unlikely to survive past 24 hours (as determined by the clinical team)
  • The patient is being transitioned to palliative care
  • Participation or Consent is declined, OR
  • Unable to identify or Contact surrogate decision maker

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine whether a strategy of adding venovenous ECMO to mechanical ventilation, as compared to mechanical ventilation alone, increases the number of intensive care free days at day 60, in patients with moderate to severe acute hypoxic respiratory failure.

The 2 groups in the trial

  • Venovenous ECMOExisting treatment, for comparison

    Patients allocated to the ECMO strategy be initiated on V-V ECMO and on anticoagulation (blood thinning medication to prevent clot formation) within 24 hours of being allocated into the intervention group. Anticoagulant medication to prevent clot formation will be initiated as per current local practice for each site. Sites are encouraged to use best practice ECMO management that includes de-sedation, extubation, commencement of physiotherapy and rehabilitation,

  • Standard careNo study treatment, for comparison

    Patients allocated to the standard care arm will receive routine intensive care for hypoxic respiratory failure, including mechanical ventilation as per local practices, weaning of sedation and assessment for extubation. Patients who continue to deteriorate will be eligible for initiation of V-V ECMO if they meet the ECMO to rescue lung injury in severe ARDS (EOLIA) criteria: Partial pressures of arterial oxygen (PaO2):Fraction of inspired oxygen (FiO2)\<50 for 3 hours, PaO2:FiO2\<80 for 6 hours, pH\<7.25 with PaCO2 \>60 for \>6 hours.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomised Controlled Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure
Fit questions
Built from NCT05562505, who can take part
Record updated
9 August 2024